Republican Congress, Trump Policies May Seek To 'Undo' FDA Device Safety Guidances; LDT Plan First To Go

Emboldened by a Republican victory in the White House, GOP members of Congress are already putting the screws on federal agencies to back off on health and safety regulations and guidances for products, with some success – for example, FDA's Nov. 18 decision to shelve its proposed laboratory developed test guidance in final form seems to be a response to the new political reality in DC.

Trump_Donald_160311_1200x675

Industry attorneys and health consultants are predicting a new policy climate in Washington for health care regulations following the Nov. 8 elections and the choice of Donald Trump as president; one of the first policies to be impacted by the new approach, is a pending laboratory-developed test oversight framework from FDA.

"Certainly a focus of the Trump campaign was reducing regulation on industry, so I do believe there will be a...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from United States

  • Global Medtech Guidance Tracker: September 2024

     
    • By 

    Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

  • Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

     

    US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.

  • Does SCOTUS Chevron Decision Tip The Scales In Favor Of Industry?

     

    With the reversal of the Chevron doctrine in June, lower courts will now have more say in deciding regulatory statutes when the language is murky. But will that open the door to more legal challenges from the healthcare industry against government regulations it finds unfavorable? A pair of legal experts recently discussed the potential implications of the Court’s decision.

  • FDA Releases Six More De Novo Summaries

     
    • By 

    The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.

More from North America